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Abstract  
BACKGROUND: Percutaneous transcatheter closure (PTC) of patent foramen ovale (PFO) is 
implicated in cryptogenic stroke, transitional ischemic attack (TIA) and treatment of a migraine. 
 
AIM: Our goal was to present our experience in the interventional treatment of PFO, as well as to 
evaluate the short and mid-term results in patients with closed PFO.
 
MATERIAL AND METHODS: Transcatheter closure of PFO was performed in 52 patients (67.3% 
women, mean age 40.7 ± 11.7 years). Patients were interviewed for subjective grading of the 
intensity of headaches before and after the PFO closure.  
RESULTS: During 2 years of follow-up, there was no incidence of new stroke, TIA and/or syncope. 
Follow-up TCD performed in 35 patients showed complete PFO closure in 20 patients (57.1%). Out 
of 35 patients, 22 (62.9%) reported having a migraine before the procedure with an intensity of 
headaches at 8.1 ± 1.9 on a scale from 1 to 10. During 2 years of follow-up, symptoms of a 
migraine disappeared in 4 (18.2%) and the remaining 18 patients reported the significant decrease 
in intensity 4.8 ± 2.04 (p = 0.0001). In addition, following PFO closure the incidence of the 
headaches decreased significantly (p = 0.0001).  
CONCLUSIONS: Percutaneous transcatheter closure of PFO is a safe and effective procedure 
showing mid-term relief of neurological symptoms in patients as well as significant reduction of 
migraine symptoms.
 
 
 
 
 
 
 
Introduction 
 
Patent foramen ovale (PFO) is a tunnel-
shaped opening between the atria that helps blood 
circulate avoiding the lungs during intrauterine life. 
Most of the PFOs spontaneously close during the first 
year of life, but some may remain open later in life. In 
an autopsy study including 965 normal hearts of the 
general population, the prevalence of PFO was 27.3% 
with progressive decline as age increases (34.3% in 
the first three decades, 25.4% in the 4
th
 to 8
th
 decade, 
and 20.2% in the 9
th
 and 10
th
 decade) [1]. Until 
recently PFO was thought to be an anatomical variant 
in different people, however, more and more evidence 
puts into question the benign nature of this anomaly 
and the relative importance of the defect is being 
reevaluated [2-4].
 
Increasing medical evidence is recognising 
the PFO as a conduit for a paradoxical embolism 
resulting in cryptogenic stroke (CS) and transitory 
ischemic attack (TIA) [5]. There are studies 
suggesting the connection of PFO with a migraine 
with aura, orthodeoxia-platypnea and decompression 
illness in divers [6-8]. The pathophysiology of the 
neurological events associated with a paradoxical 
embolism may be due to the direct transfer of venous 
blood through the PFO into the left heart chambers 
during increased right heart pressure (Valsalva 
manoeuvre) [9]. The venous blood contains 
microthrombi from the lower extremities which are 
usually filtered through the pulmonary capillaries, 
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"purifying" the blood returning to the left heart 
chambers before it enters the cerebral vasculature. 
During activities associated with increased right heart 
pressure (diving, squatting, coughing) the certain 
portion of this microthrombi filled blood enters the left 
heart via PFO and ends up in cerebral arteries 
causing microinfarcts. These can manifest as stroke, 
TIA or provoke migraine attacks [10, 11].
 
Up to 21% of women and 6% of men suffer 
from migraine attacks and 2/1000 people over 65 
years will have an ischemic stroke [12]. Up to one-
third of ischemic strokes are "cryptogenic" because 
the cause cannot be identified. A reason for this 
cryptogenic stroke could be a paradoxical embolism 
through a PFO. In younger patients with stroke, a 4-
fold greater incidence of PFO has been detected 
compared to a stroke-free control group of the same 
age and sex [13]. Co-existence of PFO with certain 
interatrial septal abnormalities like atrial septal 
aneurysm (ASA) and Chiari's network increases the 
risk of stroke [9, 14-17]. Systematic reviews have 
suggested the significant association between a 
migraine and stroke [18], PFO and stroke [19] as well 
as PFO and migraine [20, 21].
 
Percutaneous closure of PFO was first 
described as a derivative from atrial septal defect 
closure in 1992 [22]. While initial experiences with 
different devices were disappointing, in 1997 the 
Amplatzer PFO Occluder was introduced and the 
interventional technique of transcatheter PFO closure 
started showing promising results [23]. There are 
published randomised clinical trials in transcatheter 
closure of PFO that failed to reach the primary 
endpoint [23-25]. However, the RESPECT 
(Randomized Evaluation of Recurrent Stroke 
Comparing PFO Closure to Established Current 
Standard of Care Treatment) trial showed a 7-fold 
higher stroke rate in the on-PFO closure group with 
extremely low complication rates of the procedure. 
Sub-analysis showed significant reduction of stroke 
rate in patients with larger sized PFO and atrial septal 
aneurysm [26-28]. There are 3 ongoing clinical trials 
with a total cohort of approximately 1700 patients in 
France, South Korea and Canada comparing 
interventional and medical management of PFO. 
 
Close analysis of all published data shows 
that interventional treatment of PFO is superior to 
medical treatment in the prevention of stroke and with 
the new devices and the low complication rate of the 
procedure one would expect greater implication of 
transcatheter closure technique for PFO [30].  
We set out to examine our experience with 
PTC treatment of PFO, hypothesising that 
percutaneous transcatheter closure is a safe and 
beneficial medical intervention for preventing stroke, 
TIA and reducing migraine symptoms.
 
 
Material and Methods 
 
Between 2011 and 2013, 52 patients 
underwent PTC of PFO. Stroke was diagnosed in 15 
(28.8%), repetitive TIA in 17 (32.7%), repetitive 
syncope during activities that involved Valsalva 
manoeuvre in 10 patients (19. 2%), migraine with aura 
in 7 (13.5%) and without aura in 3 (5. 8%) patients.
 
All of the patients underwent initial diagnostic 
testing with TCD. We grouped the positivity of the 
procedure by the number of bubbles that entered 
cerebral vasculature after Valsalva manoeuvre. The 
first group was a very positive test, that is, more than 
40 bubbles, the second group was with moderate 
positivity, from 20 to 39 bubbles, and the third group 
was with mildly positive transcranial Doppler test, that 
is, from 1 to 19 bubbles (Fig. 1).
 
 
Figure 1: Transcranial doppler ultrasound (TCD) in a patient with 
large PFO (over 40 bubbles)
 
 
The patients with the moderate and severe 
positivity of TCD who had an indication for PFO 
closure were further referred for TEE using the 
agitated saline solution as a contrast, where the 
presence of PFO was validated and measurements 
for the size of the device were taken (Fig. 2). Most of 
our patients had cerebral imaging performed with 
brain magnetic resonance imaging (MRI) or multislice 
computerised tomography (MSCT).
 
 
Figure 2: Transesophageal echocardiography (TEE) in a patient 
with PFO 
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The transcatheter closure of PFO was 
performed using local anaesthesia. The patients were 
informed of the procedure and a written consent was 
obtained. The PFO was crossed under fluoroscopic 
guidance through the femoral vein, with 5 F 
multipurpose catheter and hydrophilic wire, which was 
exchanged with stiff Amplatz wire. In large PFOs, we 
used balloon sizing before device implantation. We 
placed 4 (7.6%) Amplatzer PFO devices and 45 
(86.5%) Cera Occluder (Fig. 3). In 3 (5.8%) patients, 
we implanted an ASD septal occluder, due to a large 
PFO. All of the patients received a prophylactic dose 
of antibiotics. Patients were placed on dual antiplatelet 
therapy with aspirin 100 mg daily and clopidogrel 75 
mg daily for 3 months. After 3 months the clopidogrel 
was discontinued in all patients and aspirin therapy 
was maintained for an additional 3 months. 
Endocarditis prophylaxis was recommended for the 
first 6 months after the procedure. Discharge from the 
hospital took place one day after the transthoracic 
(TTE) or TEE examination. 
 
Figure 3: Percutaneous implantation of a PFO occluder 
 
The patients had echocardiographic follow-up 
at 7 days, 1 and 6 months after the procedure. Follow-
up TCD ultrasound was performed 6 and 24 months 
after the procedure. We performed 
electroencephalography (EEG) on all patients before 
the intervention. During the 2 year follow-up, patients 
were screened for neurological symptoms and events 
(CVI, TIA, syncope, migraine) during ambulatory visit 
according to the up-to-date guidelines of referent 
professional societies. After the 24 month follow-up 
period, we did a follow-up TCD, EEG and 
questionnaire interview for headaches in 35 patients. 
The remaining 17 patients were either unable or 
refused to come for follow up appointments and were 
only screened for neurological receives (TIA, stroke or 
syncope) according to their official clinical diagnosis 
by telephone interview. The thirty-five patients were 
interviewed for migraine severity graduation before 
and after the procedure. The evaluation was based on 
a questionnaire with a subjective grading of the 
intensity of headaches on a scale of 1 to 10, as well 
as frequency (1-10) of more than 10 attacks per 
month, and less than one time per month.
 
The study was approved by our ethics 
committee and participants signed informed consent 
documents. 
 
Statistics 
Continuous variables are expressed as mean 
value + SD and categorical variables as counts and 
percentages. Wilcoxon’s signed rank test was used to 
compare migraine characteristics before and after 
percutaneous PFO closure. All data analysis was 
performed using SPSS version 22.0 (IBM SPSS, Inc., 
Chicago, Illinois) and a p-value ≤ 0.05 was considered 
significant.
 
 
 
Results 
 
In 52 patients an occluder was successfully 
placed using the PTC technique. There were two 
minor complications (femoral hematoma treated 
conservatively and hypotension in one patient). We 
had one patient that complained of chest pain that 
started 24 hours after the intervention and lasted for a 
month. We assigned the symptom as a possible side 
effect of the device implantation.  
The follow-up TCD performed in 35 of the 
patients showed complete PFO closure in 20 (57.1%), 
whereas 12 patients (34.3 %) had mild (1-19 bubbles) 
and 3 patients (8.6 %) had moderate (20-39 bubbles) 
residual shunt. Over the 2 year follow-up, none of the 
patients had the recurrence of the neurological 
symptoms represented as CVI, TIA and/or syncope.
 
From 35 patients that were interviewed, 22 
(62.9%) reported having a migraine before the 
procedure. Subjective grading with the questionnaire 
showed the average intensity of headaches to be 8.1 
± 1.9, on a scale from 1 to 10 (Table 1). Following the 
procedure, over a 2 year of follow-up, symptoms of a 
migraine ceased completely in 4 patients (18.2%) and 
the remaining 18 (81.8%) patients reported the 
significant decrease in intensity to 4.8 ± 2.0 (p = 
0.0001) (Table 1). As for the frequency of headaches, 
before the procedure, it was graded as less than one 
attack per month in 3 patients (13.6%), between 1 and 
10 attacks per month in 5 patients (22.7%), and more 
than 10 attacks per month in 14 patients (63.6%). 
After the procedure, frequency of headaches 
decreased significantly with 15 patients (88.2%) 
having attacks less than once per month, 1 patient 
(5.9%) having attacks between 1 to 10 times per 
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month, and 1 patient (5.9%) having attacks more than 
10 times per month (p = 0.0001) (Table 1).  
Table 1: Comparison of intensity and frequency of the 
headaches before and after PFO closure 
 Before closure After closure p Values* 
Migraine intensity (0-10) 8.14 ± 1.9 4.8 ± 2.0 0.0001 
Frequency of headaches 
attacks (n/%) 
  <1 per month 
  1-10 per month 
  >10 per month 
 
 
3 (13.6%) 
5 (22.7%) 
14 (63.6%) 
 
 
15 (88.2%) 
1 (5.9%) 
1 (5.9%) 
 
 
0.0001 
*Before vs. after closure.  
 
In all patients who had EEG before the PFO 
closure, where findings were normal in 2 (3.8%) of the 
patients, 20 (38.5%) patients presented with irritative 
changes, 6 (11.5%) patients had changed with focal 
activity and paroxysmal discharge was seen in 24 
(46.1%) patients. We performed follow-up EEG in 35 
of the patients after 24 months of transcatheter 
closure of the PFO. EEG findings improved in 23 
(65.7%) of the patients and in 12 (34.3%) there were 
no changes in the EEG after the intervention.  
 
 
Discussion 
 
Whilst CLOSURE I (Evaluation of the 
STARFlex Septal Closure System in Patients with a 
Stroke and/or Transient Ischemic Attack due to 
Presumed Paradoxical Embolism through a Patent 
Foramen Ovale) [24] as the first randomized trial 
published on PFO closure showed that closure with a 
device did not offer a greater benefit than medical 
therapy alone for the prevention of recurrent stroke or 
TIA, results of later randomized trials showed that 
concept of PFO closure to reduce recurrent strokes 
has been proven [31, 32].
 
The difference was 
subjected to mainly shorter fixed 2-year follow-up 
period and especially lower quality of STARFLex 
device used in CLOSURE I in comparison to 
Amplatzer devices used in later studies. The meta-
analysis of Stortecky et al. included four randomised 
trials that included 2963 patients with 9309 patient-
years. The Amplatzer device showed superiority 
compared to the other two devices (STF and HLX) 
and patients who were allocated to PFO closure with 
Am player were less likely to experience a stroke than 
patients on medical therapy [rate ratio (RR) 0.39; 95% 
CI: 0.17-0.84]. However, PFO closure with any of the 
three devices showed better probability in preventing 
stroke compared to medical therapy [29]. The study of 
Wahl et al. [25] showed that PFO closure performs 
better than medical treatment. In our study, there was 
no recurrence of CVI or TIA during a 24-month follow-
up period.
 
The PREMIUM trial (Prospective Randomized 
Investigation to Evaluate Incidence of Headache 
Reduction in Subjects With Migraine and PFO Using 
the AMPLATZER PFO Occluder to Medical 
Management) was a randomized trial conducted in 29 
centers in the United States and enrolled patients 
between 18 and 64 years of age who had diagnosis of 
migraine, ranging from 6 to 14 attacks per month, with 
or without aura. The patients had PFO documented 
with TCD and their symptoms were unresponsive to 
medical therapy. A total of 226 patients had the 
femoral puncture and while some of them received the 
occluder, the remaining underwent the sham 
procedure. Patients and neurologist were blinded to 
the randomization. The results of the trial did not meet 
the pre-specified primary endpoint of 50% reduction in 
migraine attack frequency in 117 patients compared to 
103 who received a sham procedure and medical 
management. However, some secondary endpoints 
did achieve significance and 8.5%-11% of patients 
had complete migraine remission. Most of the patients 
who had complete remission had a migraine with 
aura. The conclusion of the study was that a migraine 
with aura might need different therapeutic approach 
than a migraine without aura and that maybe the key 
to different responses to PFO closure lies in the 
different anatomies of PFO and adjacent structures 
[33]. In our study migraine ceased completely in four 
patients and three of them were with a migraine with 
aura.
 
The PRIMA trial (Percutaneous Closure of 
PFO in Migraine with Aura) was conducted in 20 cities 
around the world and was prospective, randomised 
trial that included 107 participants with a migraine with 
aura who failed medical therapy. Fifty-three of them 
had PFO closure with Amplatzer device and 54 
received medical therapy. PFO closure was 
associated with the mean reduction of migraine days 
of -2.9 compared to -1.7 for medical therapy (P = 
0.17). There was numerical but not statistical 
significance. The responder rates were 37.5% for 
interventional treatment group and 14. 6% for 
conservative treatment group (P = 0.02). There was a 
complete resolution of a migraine in 10% of the 
interventional group compared to 0% in medical 
therapy group (P < 0.05). However, looking only at 
patients free of migraine attacks with aura the 
difference was pronounced with 40% in the PFO 
closure group and 10% in the control group (P = 
0.004). In PRIMA, the reduction of migraine attacks 
with aura and migraine days with aura was greater 
than the reduction of all types of migraine attacks and 
days. Therefore, this unequal and greater effect on 
migraine with aura is likely a true effect of PFO 
closure. There was only one vascular major 
complication and one transient atrial fibrillation 
reported from the interventional procedure [34]. 
A Recent meta-analysis conducted by Kent at 
al. showed that among patients with PFO and 
cryptogenic stroke, closure reduced recurrent stroke 
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and had statistically significant effect on the composite 
of stroke, TIA and death in the adjusted analysis [35].
 
In our study 22 out of 35 patients had 
migraine attacks. Ten of them went through the 
procedure only because of a migraine, but 12 had 
additional CVI, TIA or repetitive syncope. The closure 
of the PFO significantly reduced the intensity and the 
frequency of the headaches (Table 1). Four patients 
(18.2%) reported the complete absence of 
headaches, while two patients (9%) reported no 
change in intensity; however, they did report lower 
frequency of occurrence. The rest of them reported 
the significant reduction of intensity and frequency.
 
The interventional procedure of PFO closure 
is relatively efficient, depending on the type of the 
occluder used, with a very low complication rate [36-
38]. In our experience, we had only two minor 
complications (3.8%) and no major complications. 
There was one case of larger hematoma due to a 
femoral puncture and it was treated conservatively. 
The second minor complication was a patient with 
hypotension and confusion after the procedure, which 
was resolved with intravenous fluids. The follow-up 
MSCT of the brain showed no new vascular lesions. 
 
The limitations of our study included the use 
of a non-randomized sample, a small sample size and 
the possibility of recall bias for the patient-reported 
symptoms.  
In conclusion, in spite of all the published data 
until today, we still do not have clear evidence-based 
recommendations for PFO closure [39, 40]. However, 
with the usage of new devices and recently published 
studies, PFO closure procedure is more beneficial 
than harmful. Calculations say that in young people 
with a life expectancy of 50 years, 2.4 PFOs need to 
be closed in order to prevent one stroke. The 
availability of new devices and the very low 
complication rates of the procedure suggest that 
perhaps we should be more proactive towards PFO 
screening and closure. Percutaneous transcatheter 
closure of PFO is a safe and effective procedure 
showing mid-term relief of neurological symptoms 
(CVI, TIA), and significant reduction of migraine 
symptoms. However, there is a necessity of more 
studies showing results of long-term follow-up.
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